A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis c infection

PLoS Computational Biology

Volumn 8, Issue 1, 2012, Pages

  Adiwijaya, Bambang S ^a   Kieffer, Tara L ^a   Henshaw, Joshua ^a   Eisenhauer, Karen ^a   Kimko, Holly ^b   Alam, John J ^a   Kauffman, Robert S ^a   Garg, Varun ^a  

^a VERTEX PHARMACEUTICALS   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRAL AGENTS; ENZYME INHIBITION; POPULATION STATISTICS;

ANTIVIRALS; CHRONIC HEPATITIS; CHRONIC HEPATITIS C; DYNAMICS MODELS; HEPATITIS C; IN-VITRO; MECHANISTIC MODELS; PEGINTERFERON ALFA; PROTEASE INHIBITOR; RIBAVIRIN;

PATIENT TREATMENT;

PEGINTERFERON ALPHA2A; RIBAVIRIN; TELAPREVIR; VIRUS RNA; ANTIVIRUS AGENT;

ANTIVIRAL RESISTANCE; ARTICLE; COMPUTER SIMULATION; CONTROLLED STUDY; DRUG RESPONSE; DRUG TREATMENT FAILURE; ERADICATION THERAPY; HEPATITIS C; HUMAN; IC 50; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MONOTHERAPY; PREDICTION; PROGNOSIS; RELAPSE; SUSTAINED VIROLOGIC RESPONSE; VIRAL CLEARANCE; VIRUS INHIBITION; VIRUS REPLICATION; BIOLOGICAL MODEL; COMPUTER ASSISTED DRUG THERAPY; DOSE RESPONSE; DRUG EFFECT; HEPATITIS C VIRUS; METHODOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; VIROLOGY;

HEPATITIS C VIRUS;

ANTIVIRAL AGENTS; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMPUTER-ASSISTED; HEPACIVIRUS; HEPATITIS C; HUMANS; MODELS, BIOLOGICAL;

EID: 84857474172     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1002339     Document Type: Article

References (42)

1. WHO (2000) Hepatitis C - global prevalence (updates). pp. 18-19 World Health Org Weekly Epidemiol Rec: World Health Organization.
2. Bisceglie AM, Lyra AC, Schwartz M, Reddy RK, Martin P, et al. (2003) Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol 98: 2060-2063.
3. El-Serag HB, Mason AC, (1999) Rising Incidence of Hepatocellular Carcinoma in the United States. N Engl J Med 340: 745-750.
4. Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, et al. (2010) Hepatocellular Carcinoma: Consensus Recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 28: 3994-4005.
5. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, et al. (2002) Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection. N Engl J Med 347: 975-982.
6. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965.
7. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, et al. (2009) Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection. New England Journal of Medicine 360: 1827-1838 [Erratum, N Engl J Med 2009;1361:1516].
8. Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, et al. (2009) Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection. N Engl J Med 360: 1839-1850.
9. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, et al. (2010) Telaprevir for Previously Treated Chronic HCV Infection. N Engl J Med 362: 1292-1303.
10. Marcellin P, Forns X, Goeser T, Ferenci P, Nevens F, et al. (2011) Telaprevir Is Effective Given Every 8 or 12 Hours With Ribavirin and Peginterferon Alfa-2a or-2b to Patients With Chronic Hepatitis C. Gastroenterology 140: 459-468.e451.
11. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, et al. (2011) Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection. N Engl J Med 364: 2405-2416.
12. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, et al. (2011) Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection. N Engl J Med 365: 1014-1024.
13. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, et al. (2011) Telaprevir for Retreatment of HCV Infection. N Engl J Med 364: 2417-2428.
14. Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, et al. (2008) Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology 48: 1769-1778.
15. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, et al. (2007) Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor Telaprevir. Gastroenterology 132: 1767-1777.
16. Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, et al. (2007) Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46: 631-639.
17. Susser S, Welsch C, Wang Y, Zettler M, Domingues FS, et al. (2009) Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 50: 1709-1718.
18. Adiwijaya BS, Herrmann E, Hare B, Kieffer T, Lin C, et al. (2010) A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the In Vivo Evolution of Protease-Inhibitor Resistant Variants. PLoS Comput Biol 6: e1000745.
19. Rong L, Dahari H, Ribeiro RM, Perelson AS, (2010) Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus. Sci Transl Med 2: 30ra32.
20. Lin K, Kwong AD, Lin C, (2004) Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Antimicrob Agents Chemother 48: 4784-4792.
21. Forestier N, Reesink HW, Weegink CJ, McNair L, Kieffer TL, et al. (2007) Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 46: 640-648.
22. Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, et al. (2008) Natural prevalence of HCV variants with decreased susceptibility to NS3•4A protease inhibitors in treatment-naïve subjects. J Infect Dis 198: 797.
23. Adiwijaya BS, Hare B, Caron PR, Randle JR, Neumann AU, et al. (2009) Rapid decline of wild-type Hepatitis-C virus on telaprevir treatment. Antivir Ther 14: 591-595.
24. Dahari H, Guedj J, Colter SJ, Layden TJ, Perelson AS, (2010) Higher hepatitis C virus (HCV) clearance rates during treatment with direct acting agents compared to intereferon-alpha. Hepatology 52: 718A.
25. Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS, (2004) Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 432: 922-924.
26. Snoeck E, Chanu P, Lavielle M, Jacqmin P, Jonsson EN, et al. (2010) A comprehensive hepatitis C viral kinetic model explaining cure. Clin Pharmacol Ther 87: 706-713.
27. Guedj J, Perelson AS, (2011) Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: Implications for treatment duration. Hepatology 53: 1801-1808.
28. Adiwijaya BS, Kieffer TL, Bartels DJ, Picchio G, De Meyer S, et al. (2011) Modeling, clinical and virology data from Phase 2 and 3 studies support 12-week telaprevir duration in combination with 24- or 48-week peginterferon/ribavirin duration. J Hepatol 54: S160.
29. Kieffer TL, Bartels DJ, Sullivan J, Adiwijaya BS, Zhang EZ, et al. (2010) Clinical Virology Results from Telaprevir Phase 3 Study ADVANCE. Hepatology 52: LB-11.
30. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.
31. Bochud PY, Bibert S, Negro F, Haagmans B, Soulier A, et al. (2011) IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. J Hepatol 55: 980-988.
32. de Araujo ES, Dahari H, Cotler S, Layden T, Neumann A, et al. (2011) Pharmacodynamics of PEG-IFN alpha-2a and HCV response as a function of IL28B polymorphism in HIV/HCV co-infected patients. J Acquir Immune Defic Syndr 56: 95-99.
33. Reesink HW, Zeuzem S, Weegink CJ, Forestier N, van Vliet A, et al. (2006) Rapid Decline of Viral RNA in Hepatitis C Patients Treated With VX-950: A Phase Ib, Placebo-Controlled, Randomized Study. Gastroenterology 131: 997-1002.
34. Wade JR, Snoeck E, Duff F, Lamb M, Jorga K, (2006) Pharmacokinetics of ribavirin in patients with hepatitis C virus. British Journal of Clinical Pharmacology 62: 710-714.
35. Mackay IR, (2002) Hepatoimmunology: A perspective. Immunol Cell Biol 80: 36-44.
36. Ogata N, Alter HJ, Miller RH, Purcell RH, (1991) Nucleotide-Sequence and Mutation-Rate of the H-Strain of Hepatitis-C Virus. Proc Natl Acad Sci U S A 88: 3392-3396.
37. Lindenbach BD, Rice CM, (2001) Flaviviridae: the viruses and their replication. In: Knipe DM, Howley PM, Griffin DE, editors. Fields Virology. Fourth ed Lippincott Williams and Wilkins pp. 991-1041.
38. Lin K, Perni RB, Kwong AD, Lin C, (2006) VX-950, a novel hepatitis c virus (hcv) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrob Agents Chemother 50: 1813-1822.
39. Zhou Y, Muh U, Hanzelka BL, Bartels DJ, Wei Y, et al. (2007) Phenotypic and Structural Analyses of Hepatitis C Virus NS3 Protease Arg155 Variants: Sensitivity to Telaprevir (VX-950) and interferon alpha. J Biol Chem 282: 22619-22628.
40. Zhou Y, Bartels D, Hanzelka B, Muh U, Wei Y, et al. (2008) Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 52: 110-120.
41. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, et al. (1998) Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282: 103-107.
42. Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, et al. (2001) Viral Kinetics in Patients With Chronic Hepatitis C Treated With Standard or Peginterferon [alpha]2a. Gastroenterology 120: 1438-1447.